Critical review of EU BE guideline (Rev.1) [Regulatives / Guidelines]

posted by banusunman – 2008-08-26 18:56 (6142 d 09:54 ago) – Posting: # 2256
Views: 24,270

Dear all,

Here is another one:

On page 5, line 150-151 — the criterion for "adequate wash-out period" is not defined. However, in the previous 2001 NfG, for steady-state designs, it was given as "at least 3-times the terminal half-life". In FDA's 2003 GfI, an adequate washout period was described as "e.g., more than 5 half lives of the moieties to be measured".

Do you think they forgot to define it.. or?

Regards,

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
48 visitors (0 registered, 48 guests [including 10 identified bots]).
Forum time: 04:51 CEST (Europe/Vienna)

Medical researches can be divided into two sorts:
those who think that meta is better and those
who believe that pooling is fooling.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5